Home Depot's CEO says the retailer cut its outlook partly due to "the potential impacts to the U.S. consumer arising from recently announced tariffs."Retailread more
For investors still haunted by last week's monster sell-off, the market's comeback is set to last, according to J.P. Morgan's quant guru.Marketsread more
A U.S.-China trade deal would be less likely if President Xi cracks down violently on the large-scale protests in Hong Kong, Secretary of State Mike Pompeo tells CNBC.Politicsread more
The launch follows a "preview" earlier this month that allowed only limited customers to apply.Technologyread more
Financial advisers are always "buying at the wrong time and selling at the wrong time because they're emotional," the billionaire founder of Baron Capital says.Marketsread more
Energy stocks may be fueling up for a comeback rally. One technical analyst says that after the sector's pummeling, these two stocks look particularly good.Trading Nationread more
Bruce Linton says he bought more stock in Canopy Growth — even though the cannabis company he co-founded fired him earlier this summer.Health and Scienceread more
"We think the stock is appealing once again," J.P. Morgan says of Beyond Meat.Marketsread more
A new probe could bring more pressure to some of the nation's largest tech firms, which are already facing federal scrutiny.Technologyread more
Got extra stuff? Got extra space? A new company is ready to make a match. Neighbor is a barely two-year-old company that connects homeowners online with people who need...Real Estateread more
The company confirmed it's hiring a team of veteran journalists to help curate news stories in its soon-to-launch news tab.Technologyread more
WASHINGTON, Feb 25 (Reuters) - An appeals court on Monday upheld a judge's decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market.
The 3rd U.S. Circuit Court of Appeals ruled that a federal court in Delaware had been correct in dismissing the FTC's lawsuit against Shire. Shire was acquired by Takeda Pharmaceutical Co last month.
The agency had objected to ViroPharma, which Shire acquired in 2014, filing 46 "citizen petitions" and other filings between 2006 and 2012 to the U.S. Food and Drug Administration regarding generic equivalents to its antibiotic Vancocin HCl, on the grounds that it resulted in delayed sale of a generic version.
But while the appeals court acknowledged that the delayed entry meant "hundreds of millions of dollars in profits," it said that the petitioning activity had ceased and thus the company was not in violation of the law. This ruling agreed with what the lower court had said in March 2018.
The FTC said it "regrets the courts decision and is considering its options." Shire owner Takeda did not immediately respond to a request for comment. (Reporting by Diane Bartz)